These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11979070)

  • 21. Pathology of tumor-stroma interaction in melanoma metastatic to the skin.
    Smolle J; Woltsche I; Hofmann-Wellenhof R; Haas J; Kerl H
    Hum Pathol; 1995 Aug; 26(8):856-61. PubMed ID: 7635447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
    Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
    Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
    Salti GI; Manougian T; Farolan M; Shilkaitis A; Majumdar D; Das Gupta TK
    Cancer Res; 2000 Sep; 60(18):5012-6. PubMed ID: 11016620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of two morphologic parameters concerning tumor-stroma interaction in benign and malignant melanocytic skin lesions.
    Fink-Puches R; Smolle J; Hofmann-Wellenhof R; Kerl H
    Am J Dermatopathol; 1998 Oct; 20(5):468-72. PubMed ID: 9790107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thin melanoma.
    Elder DE
    Arch Pathol Lab Med; 2011 Mar; 135(3):342-6. PubMed ID: 21366458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stromal reaction in cutaneous melanoma.
    Labrousse AL; Ntayi C; Hornebeck W; Bernard P
    Crit Rev Oncol Hematol; 2004 Mar; 49(3):269-75. PubMed ID: 15036266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma.
    Oba J; Nakahara T; Hayashida S; Kido M; Xie L; Takahara M; Uchi H; Miyazaki S; Abe T; Hagihara A; Moroi Y; Furue M
    J Am Acad Dermatol; 2011 Dec; 65(6):1152-60. PubMed ID: 21700362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
    Nahabedian MY; Tufaro AP; Manson PN
    Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metallothionein-overexpression as a prognostic marker in melanoma.
    Weinlich G
    G Ital Dermatol Venereol; 2009 Feb; 144(1):27-38. PubMed ID: 19218909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutaneous melanomas exhibiting unusual biologic behavior.
    Shaw HM; Rivers JK; McCarthy SW; McCarthy WH
    World J Surg; 1992; 16(2):196-202. PubMed ID: 1561799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
    Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
    Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic analysis of 66 Japanese thin melanomas with metastasis of sentinel or regional lymph node.
    Mori M; Sugiura M; Kono M; Matsumoto T; Sawada M; Yokota K; Yasue S; Shibata S; Sakakibara A; Nakamura S; Tomita Y; Akiyama M
    J Cutan Pathol; 2013 Dec; 40(12):1027-34. PubMed ID: 24111935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
    Thies A; Moll I; Berger J; Wagener C; Brümmer J; Schulze HJ; Brunner G; Schumacher U
    J Clin Oncol; 2002 May; 20(10):2530-6. PubMed ID: 12011132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery.
    Majewski W; Stanienda K; Wicherska K; Ulczok R; Wydmanski J
    Asian Pac J Cancer Prev; 2015; 16(14):5709-14. PubMed ID: 26320440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of the sentinel lymph node in malignant melanomas.
    Bachter D; Michl C; Büchels H; Vogt H; Balda BR
    Recent Results Cancer Res; 2001; 158():129-36. PubMed ID: 11092040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
    Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
    Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanoma of the ear: prognostic factors and surgical strategies.
    Jahn V; Breuninger H; Garbe C; Moehrle M
    Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous "leiomyosarcoma".
    Kraft S; Fletcher CD
    Am J Surg Pathol; 2011 Apr; 35(4):599-607. PubMed ID: 21358302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.